NYSE:HIMSHealthcare
A Look At Hims & Hers (HIMS) Valuation After Regulatory Setbacks And Softer Revenue Outlook
Hims & Hers Health (HIMS) is back in the spotlight after its Q4 2025 earnings per share beat, which contrasted with softer Q1 2026 revenue guidance and mounting regulatory and legal pressures.
See our latest analysis for Hims & Hers Health.
Those mixed earnings and guidance headlines have landed on a stock that was already under pressure, with a 30 day share price return of 47.44% declines and a year to date share price return of 53.31% declines. The 1 year total shareholder return is a...